Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
May 31, 2012
Primary Completion Date
December 31, 2013
Conditions
Morbid Obesity
Interventions
DRUG
Sugammadex 1 mg/kg
DRUG
Sugammadex 2 mg/kg
DRUG
Sugammadex 4 mg/kg
Trial Locations (1)
86021
CHU de Poitiers, Poitiers
All Listed Sponsors
lead
Poitiers University Hospital
OTHER
NCT02545595 - Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients | Biotech Hunter | Biotech Hunter